Request for Covid-19 Impact Assessment of this Report
The global BCG vaccine market is estimated to reach $28,051 thousand by 2023, growing at a CAGR of 4.6% from 2017 to 2023, from $20,366 thousand in 2016. Bacillus Calmette-Guérin (BCG) vaccine is the only vaccine available for prevention of human forms of tuberculosis (TB). This vaccine is generally administered to children at birth in countries with high incidence of TB. In regions with low level of TB, only children at high risk are typically immunized, whereas adults are generally not immunized. However, adults (up to the age of 35) who are frequently exposed to drug-resistant TB may also be given BCG vaccine.
The global BCG vaccine market is driven by increase in prevalence of tuberculosis and rise in technological advancements in vaccine research. Moreover, the increase in government initiatives and focus on immunization programs globally boost the market growth. However, side effects of BCG vaccine and a global shortage of BCG vaccine restrain this growth. Untapped market potential in developing regions is expected to present numerous opportunities for market development.
The global BCG vaccine market is segmented on the basis of demographics and country. Based on demographics, it is bifurcated into pediatrics (0-18 years), and adults (19-35 years. Based on country, it is analyzed across India, China, Bangladesh, Pakistan, Indonesia, Japan, Brazil, Mexico, South Africa, Kenya, Thailand, Argentina, Colombia, Chile, Singapore, and rest of the world.
KEY BENEFITS FOR STAKEHOLDERS
KEY MARKET SEGMENTS
BY DEMOGRAPHICS
BY COUNTRY
LIST OF KEY PLAYERS PROFILED IN THE REPORT
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.1.1. Secondary research
1.1.2. Primary research
1.1.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.2.2.1. Competitive intelligence of companies and their strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.4.4. Impact analysis
3.5. CLINICAL TRIALS
CHAPTER 4 GLOBAL BCG VACCINE MARKET, BY DEMOGRAPHICS
4.1. OVERVIEW
4.1.1. Key market trends
4.1.2. Growth factors and opportunities
4.1.3. Market size and forecast
4.2. PEDIATRICS (AGE 0-18 YEARS)
4.2.1. Market size and forecast
4.3. ADULTS (AGE 19-35 YEARS)
4.3.1. Market size and forecast
CHAPTER 5 BCG VACCINE MARKET, BY COUNTRY
5.1. OVERVIEW
5.1.1. Key market trends
5.1.2. Growth factors and opportunities
5.1.3. Market size and forecast
5.2. INDIA
5.2.1. Market size and forecast
5.3. CHINA
5.3.1. Market size and forecast
5.4. BANGLADESH
5.4.1. Market size and forecast
5.5. PAKISTAN
5.5.1. Market size and forecast
5.6. INDONESIA
5.6.1. Market size and forecast
5.7. JAPAN
5.7.1. Market size and forecast
5.8. BRAZIL
5.8.1. Market size and forecast
5.9. MEXICO
5.9.1. Market size and forecast
5.10. SOUTH AFRICA
5.10.1. Market size and forecast
5.11. KENYA
5.11.1. Market size and forecast
5.12. THAILAND
5.12.1. Market size and forecast
5.13. ARGENTINA
5.13.1. Market size and forecast
5.14. COLOMBIA
5.14.1. Market size and forecast
5.15. CHILE
5.15.1. Market size and forecast
5.16. SINGAPORE
5.16.1. Market size and forecast
5.17. REST OF THE WORLD
5.17.1. Market size and forecast
CHAPTER 6 COMPANY PROFILES
6.1. CHINA NATIONAL BIOTEC GROUP (A SUBSIDIARY OF CHINA NATIONAL PHARMACEUTICAL GROUP CORPORATION)
6.1.1. Company overview
6.1.2. Operating business segments
6.1.3. Business performance
6.1.4. Key strategic moves and developments
6.2. GREENSIGNAL BIO PHARMA LIMITED
6.2.1. Company overview
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves and developments
6.3. INTERVAX LTD.
6.3.1. Company overview
6.3.2. Operating business segments
6.3.3. Business performance
6.3.4. Key strategic moves and developments
6.4. JAPAN BCG LABORATORY
6.4.1. Company overview
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves and developments
6.5. MERCK & CO., INC.
6.5.1. Company overview
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves and developments
6.6. SANOFI PASTEUR
6.6.1. Company overview
6.6.2. Operating business segments
6.6.3. Business performance
6.6.4. Key strategic moves and developments
6.7. SERUM INSTITUTE OF INDIA PVT. LTD.
6.7.1. Company overview
6.7.2. Operating business segments
6.7.3. Business performance
6.7.4. Key strategic moves and developments
6.8. STATENS SERUM INSTITUT
6.8.1. Company overview
6.8.2. Operating business segments
6.8.3. Business performance
6.8.4. Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL BCG VACCINE MARKET, BY DEMOGRAPHICS, 2016-2023 ($MILLION)
TABLE 2. PEDIATRIC BCG VACCINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 3. ADULT BCG VACCINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 4. BCG VACCINE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 5. INDIA BCG VACCINE MARKET, BY DEMOGRAPHICS, 2016-2023 ($MILLION)
TABLE 6. CHINA BCG VACCINE MARKET, BY DEMOGRAPHICS, 2016-2023 ($MILLION)
TABLE 7. BANGLADESH BCG VACCINE MARKET, BY DEMOGRAPHICS, 2016-2023 ($MILLION)
TABLE 8. PAKISPAN BCG VACCINE MARKET, BY DEMOGRAPHICS, 2016-2023 ($MILLION)
TABLE 9. INDONESIA BCG VACCINE MARKET, BY DEMOGRAPHICS, 2016-2023 ($MILLION)
TABLE 10. JAPAN BCG VACCINE MARKET, BY DEMOGRAPHICS, 2016-2023 ($MILLION)
TABLE 11. BRAZIL BCG VACCINE MARKET, BY DEMOGRAPHICS, 2016-2023 ($MILLION)
TABLE 12. MEXICO BCG VACCINE MARKET, BY DEMOGRAPHICS, 2016-2023 ($MILLION)
TABLE 13. SOUTH AFRICA BCG VACCINE MARKET, BY DEMOGRAPHICS, 2016-2023 ($MILLION)
TABLE 14. KENYA BCG VACCINE MARKET, BY DEMOGRAPHICS, 2016-2023 ($MILLION)
TABLE 15. THAILAND BCG VACCINE MARKET, BY DEMOGRAPHICS, 2016-2023 ($MILLION)
TABLE 16. ARGENTINA BCG VACCINE MARKET, BY DEMOGRAPHICS, 2016-2023 ($MILLION)
TABLE 17. COLOMBIA BCG VACCINE MARKET, BY DEMOGRAPHICS, 2016-2023 ($MILLION)
TABLE 18. CHILE BCG VACCINE MARKET, BY DEMOGRAPHICS, 2016-2023 ($MILLION)
TABLE 19. SINGAPORE BCG VACCINE MARKET, BY DEMOGRAPHICS, 2016-2023 ($MILLION)
TABLE 20. REST OF THE WORLD BCG VACCINE MARKET, BY DEMOGRAPHICS, 2016-2023 ($MILLION)
TABLE 21. CHINA NATIONAL BIOTEC: COMPANY SNAPSHOT
TABLE 22. GSBPL: COMPANY SNAPSHOT
TABLE 23. INTERVAX: COMPANY SNAPSHOT
TABLE 24. JAPAN BCG LABORATORY: COMPANY SNAPSHOT
TABLE 25. MERCK: COMPANY SNAPSHOT
TABLE 26. SANOFI: COMPANY SNAPSHOT
TABLE 27. SERUM INSTITUTE OF INDIA: COMPANY SNAPSHOT
TABLE 28. STATENS SERUM INSTITUT: COMPANY SNAPSHOT
LIST OF FIGURES
FIGURE 1. ENT & BRONCHOSCOPY DEVICES MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2014-2016)
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 5. TOP COMPANIES AND THEIR STRATEGIES
FIGURE 6. DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
FIGURE 7. DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIGURE 8. MARKET SHARE ANALYSIS, BCG VACCINE MARKET, 2016 (%)
FIGURE 9. IMPACT ANALYSIS: BCG VACCINE MARKET
FIGURE 10. CLINICAL TRIALS CONDUCTED IN BCG VACCINE MARKET
Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...
The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billio...